Loading chat...
NJ A5409
Bill
Status
3/6/2025
Primary Sponsor
Linda Carter
Click for details
AI Summary
-
NJ FamilyCare must reimburse long-acting injectable antipsychotic drugs administered in inpatient settings separately from Diagnostic Related Group (DRG) payments, at the same rate as outpatient administration
-
Long-acting injectable antipsychotics are defined as FDA-approved medications treating schizophrenia and bipolar disorder that provide up to 24 weeks of treatment with a single dose
-
Pharmacists may administer long-acting injectable antipsychotic drugs pursuant to a prescription, provided they meet education and qualification requirements established by the State Board of Pharmacy and Board of Medical Examiners
-
Commissioner of Human Services must apply for federal Medicaid waivers or state plan amendments necessary to implement these provisions
-
Takes effect on the first day of the fourth month following enactment
Legislative Description
Requires NJ FamilyCare to reimburse inpatient providers for long-acting injectable antipsychotic drugs at outpatient reimbursement rate.
Health
Last Action
Reported out of Asm. Comm. with Amendments, and Referred to Assembly Health Committee
12/4/2025